Literature DB >> 541003

Clinical profile of cases of kala-azar in Bihar.

B K Aikat, S Sahaya, A G Pathania, P K Bhattacharya, N Desai, L S Prasad, S Mishra, S Jain.   

Abstract

Mesh:

Year:  1979        PMID: 541003

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


× No keyword cloud information.
  7 in total

Review 1.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

2.  Effectiveness of Short-Course Meglumine Antimoniate (Glucantime®) for Treatment of Visceral Leishmaniasis: A 13-Year, Multistage, Non-Inferiority Study in Iran.

Authors:  Abdolvahab Alborzi; Gholamreza Pouladfar; Armin Attar; Fatemeh Falahi; Zahra Jafarpour; Abdollah Karimi; Mohammad Rahim Kadivar
Journal:  Am J Trop Med Hyg       Date:  2016-11-22       Impact factor: 2.345

3.  Drug resistance in leishmaniasis.

Authors:  Jaya Chakravarty; Shyam Sundar
Journal:  J Glob Infect Dis       Date:  2010-05

4.  Immune complexes in Indian kala-azar.

Authors:  S Sehgal; B K Aikat; A G Pathania
Journal:  Bull World Health Organ       Date:  1982       Impact factor: 9.408

5.  Efficacy of amphotericin B in multi-drug resistant kala-azar in children in first decade of life.

Authors:  C P Thakur; G P Sinha; V Sharma; A K Pandey; P K Sinha; D Barat
Journal:  Indian J Pediatr       Date:  1993 Jan-Feb       Impact factor: 1.967

6.  Use of antimony in the treatment of leishmaniasis: current status and future directions.

Authors:  Arun Kumar Haldar; Pradip Sen; Syamal Roy
Journal:  Mol Biol Int       Date:  2011-06-08

Review 7.  The lost hope of elimination of Kala-azar (visceral leishmaniasis) by 2010 and cyclic occurrence of its outbreak in India, blame falls on vector control practices or co-infection with human immunodeficiency virus or therapeutic modalities?

Authors:  Mayilsamy Muniaraj
Journal:  Trop Parasitol       Date:  2014-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.